Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation
Eris Proposes to acquire India Branded Formulations business of Biocon Biologics and 19% stake in Swiss Parenterals Limited14-03-2024
14-03-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Acquisition
Acquisition of 19% in stake in Swiss Parenterals Limited14-03-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dear Sir/Madam, We wish to inform that pursuant to regulation 30 and other applicable regulations, if any, of the SEBI LODR, 2015 the Company will hold a conference call for analysts and investors on Thursday, 14th March, 2024 at 04:30 PM, IST. The details of the said call are attached herewith and are also available on the Company's website.14-03-2024
Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING HELD TODAY, I.E., MARCH 14, 2024
Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in its meeting held today, i.e., 14th March, 2024, inter alia, duly approved/took on record the following: ? Agreement to acquire the Branded Formulations businesses of Biocon Biologics Limited pertaining to the Indian Territory to the extent and in the manner mentioned therein. ? Agreement to acquire 19% equity stake in Swiss Parenterals Limited from the Promoters of the Company. In compliance with the SEBI Circular dated July 13, 2023 bearing reference number SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123, the additional details given under the attached Annexures. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 03:05 P.M.14-03-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING27-02-2024
Buy Eris Lifesciences; target of Rs 1100: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated February 23, 2024.26-02-2024
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Analyst and Investor Call20-02-2024
Eris Lifesciences Ltd - 540596 - UPDATE ON ACQUISITION OF 51% EQUITY STAKE IN SWISS PARENTERALS LIMITED.
closure of acquisition15-02-2024
Eris Lifesciences Q3 Results Review- Strong All-Round Performance; Forays Into Parenteral Segment: Nirmal Bang
On Track To Diversify Credit Card Sourcing Mix.15-02-2024